secwatch.observer — SEC 8-K summary
======================================

Issuer:     Imunon, Inc. (IMNN)
CIK:        0000749647
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001493152-24-018166
Event type: leadership
Sentiment:  positive
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imunon appoints Dr. Stacy R. Lindborg as President and CEO effective May 13
---------------------------------------------------------------------------

- Employment agreement: $567,000 base salary, 100% target bonus, 225,000 stock options vesting over 4 years, $200,000 sign-on bonus.
- Dr. Lindborg brings 30 years of pharma/biotech experience; most recently co-CEO of BrainStorm Cell Therapeutics (BCLI).
- Phase 2 OVATION 2 topline results for IMNN-001 (ovarian cancer) expected by mid-summer; Phase 1 COVID-19 vaccine data by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/749647/000149315224018166/0001493152-24-018166-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/749647/000149315224018166/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-018166

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer